T:10.5 in S:9.5 in
for reducing stroke risk in nonvalvular AF
for treatment of DVT
for treatment of PE for reduction in the risk of recurrence of DVT and of PE for the prophylaxis of DVT after knee replacement surgery
B:14.25 in T:14 in S:13 in S:13 in
T:14 in
for the prophylaxis of DVT after hip replacement surgery
for >90% of your insured patients,1 at the lowest branded co-pay for: >85% of commercial patients1 >85% of Medicare patients1
Broad formulary coverage
>2 million US prescriptions2 >4 million patients treated worldwide3
Real-world experience
APPROVED FOR MULTIPLE INDICATIONS
CSWN_ACCEL_8'13.indd 23
8/19/13 5:08 PM